XII Encuentro de Cooperación Farma-Biotech

Santiago de Compostela, 26 de septiembre de 2014

Innovative pharmacological treatment for retinal dystrophies





MEDICAMENTOS INNOVADORES Plataforma Tecnológica Española



Content

1. ANKAR PHARMA and the current pipeline

- 2. AP-1
 - Target Indications
 - Innovative aspects
 - Current status of development: proof of concept and trials already performed
 - Differential features facing the market and business opportunities
 - IPR protection
 - Pitfalls & Risks to be considered

















ANKAR PHARMA is a Spanish biotech company, a spin-off of CSIC **CSIC** founded in February 2014

Mission

Objectives

Business Model



Develop drugs that cure or increase the quality of life of patients suffering from neurodegenerative diseases, reducing the time span between drug investigation and market introduction


Develop successful pre-clinical trials for new innovative drug candidates for neurological diseases and metabolic disorders

Acquired promising innovative drug molecules from CSIC, develop successful IND-enabling tasks and offer them to the pharmaceutical industry for clinical development and market registration







ANKAR PHARMA









Drug development: AP-1









First Targeted disease: Multiple Sclerosis


- MS is the most common chronic, no-traumatic disabling CNS disease affecting young adults, affecting 2 Million persons worldwide.
- Age and gender:
 - MS is diagnosed frequently between ages of 20-40 years
 - It is more frequent in women than in men (2:1 ratio up to 3:1 ratio in most recent reviews)

Ratio per 100.000	Prevalence	Incidence
Europe region	>30	
Scotland and Northern Ireland	>200	
UK	203	9.6
Iberian peninsula	72-77	2.2-5
France	95	7.5
Central European countries	62-128	
US	135	
China	1	
India	3	
Asia	1-5	
Germany	149	
Global	30	2.5




MS: drug competitors

• Several improvements have been made in the recent years in the treatment of MS patients, thanks to the introduction of new therapies.





Multiple Sclerosis: Innovative approach





New Treatment: AP-1

AP-1

first-in-class product candidate for the treatment of MS

Innovative MoA: neuroprotection, remyelinization and antinflammation high activity in all key components associated to MS (EAE model) decrease of clinical symptoms (neurological score) reduce inflammation increase neuroprotection and remyelinazation

good pharmacokinetic profile compatible with clinical trials

Patent protection

•AP-1 compound is strongly protected by national patent covering all ITDZs compounds and its use in neurodegenerative disease.


•Initial patent (**ES**2360783 (**B1**) 22.06.2012) is now in national phase for the following territories:

USA: US2012225879 (A1) (02.04.2012) EU: EP2484670 (27.04.2012) Australia: AU2010302536 (A1) (27.04.2012) Canada: CA2780695 (27.04.2012)




AP-1 Development plan

Until 2014 Investment in Research reached a total of 2 Million euros to obtain all the evidence supporting the efficacy of this triple mechanism of action in EAE, PD and AD.





Second Targeted disease: Retinitis pigmentosa





Second Targeted disease: Retinitis pigmentosa

Retinitis pigmentosa (**RP**) is an inherited, degenerative eye disease that causes severe vision impairment and often blindness. RP is characterized by the progressive loss of photoreceptor cells.


Currently there is no cure for retinitis pigmentosa,

	Tasa de prevalencia por					
Territorio	mil habitantes	2005	2010	2015	2020	2025
España	3 <i>00</i> 0	<i>14.4</i> 66	15.036	15333	15.482	15.541
Uhión Europea	4.000	115.370	116.000	116.750	117.325	117.525
EW	4.000	74.912	78.673	82.253	85.637	88.733
Canadá	4.000	8.068	8.438	8.798	9.147	9.478
Australia	4.000	5.078	5.341	5.599	5.855	6.098
Japón	4.000	31.974	31.940	31.652	31.122	30.404
Total		235.401	240.391	245.051	249.086	252.237

Rare disease



New Treatment: AP-1





15




rd10 mice


New Treatment: AP-1





Death model: photoreceptor cells of rd10 mouse






GSK-3 inhibitors, including **AP-1**, protect the photoreceptor cell of rd10 mice retinas.

In vivo functional evaluation of **AP-1** in

rd10 mice.

12



Strategic Business Leverages










Strategic Business Leverages

Qualitative actions that improve P&L





Strategic Business Leverages

Qualitative actions that improve P&L

Close relationship R&D institutions



- In-depth knowledge of CSIC patent opportunities
- Focused knowledge in international researches pertaining neurodegenerative diseases
- Members of different international consortiums for research on neurodegenerative disorders



Qualitative actions that improve P&L

Alliances with Pharma & Biotech companies



- Reaching Co-research agreements with several biotech companies for the application of AP-1 in several diseases:
 - Retinitis Pigmentosa
 - Alzheimer
 - Autism
 - ALS



Qualitative actions that improve P&L



- Same trials costs for developing more than one therapeutical target
- Alternative global suppliers vs. local
- Active search for public and private grants



Strategic Business Leverages

Qualitative actions that improve P&L

- <u>MS with AP-1</u>. Objective: Clinical trial phase
- Secondary objective: short-term results. Initiate <u>orphan drug</u> status for retinosis pigmentosa
- De-risking strategy: Obtain patent of a drug in <u>clinical phase</u> to begin neurodegenerative orphan drug clinical trials with patients.

Drug portfolio management



De-risking Strategies

Acknowledgements







Dra. Carmen Gil Dra. Valle Palomo Dr. Daniel Perez Dra. Concha Perez

Dr. E. de la Rosa





Dr. P de la Villa





MEDICAMENTOS INNOVADORES Plataforma Tecnológica Española

